Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Nuo Therapeutics sales and marketing update

    Nuo Therapeutics Inc. (OTCQX:CMXI), Gaithersburg, Md. Business: Dermatology Nuo Therapeutics (formerly Cytomedix Inc.) re-launched its AutoloGel System in the U.S. under the Aurix System brand. The device produces …

    Published on 10/27/2014
  • Metamark Genetics sales and marketing update

    Metamark Genetics Inc., Cambridge, Mass. Business: Diagnostic Metamark launched the ProMark prostate cancer biopsy test in the U.S. to improve prognosis accuracy. Metamark, which acquired the HealthTronics Laboratories …

    Published on 10/20/2014
  • Pathway Genomics sales and marketing update

    Pathway Genomics Corp., San Diego, Calif. Business: Diagnostic Pathway launched its BreastTrue High Risk Panel. The next-generation sequencing test with deletion/duplication analysis detects mutations in seven high-risk…

    Published on 10/20/2014
  • Genetic Technologies sales and marketing update

    Genetic Technologies Ltd. (ASX:GTG; NASDAQ:GENE), Fitzroy, Australia Business: Diagnostic Genetic Technologies' Phenogen Sciences Inc. subsidiary launched BREVAGenplus in the U.S. to assess a women's risk of developing …

    Published on 10/13/2014
  • Leo Pharma sales and marketing update

    Leo Pharma A/S, Ballerup, Denmark Business: Dermatology Leo Pharma's Leo Pharma Inc. subsidiary launched Taclonex calcipotriene/betamethasone dipropionate to treat plaque psoriasis of the scalp in patients 12-17 years …

    Published on 10/13/2014
  • MyCartis sales and marketing update

    MyCartis N.V., Lausanne, Switzerland Business: Diagnostic MyCartis launched the Evaluation biomarker analysis platform. The digital multiplex platform analyzes protein and nucleic acid-based biomarkers for …

    Published on 10/13/2014
  • Mylan sales and marketing update

    Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Business: Infectious Mylan launched a generic form of Combivir lamivudine/zidvudine from ViiV Healthcare Ltd. (Brentford, U.K.) in the U.S. to treat HIV-1 infection. The …

    Published on 10/13/2014
  • Orexo sales and marketing update

    Orexo AB (SSE:ORX; OTCQX:ORXOY), Uppsala, Sweden Business: Neurology Orexo launched a patient assistance program in the U.S. to provide Zubsolv buprenorphine/naloxone to treat opioid dependence for free to 1,000 …

    Published on 10/13/2014
  • Aastrom sales and marketing update

    Aastrom Biosciences Inc. (NASDAQ:ASTM), Ann Arbor, Mich. Business: Gene/Cell therapy, Dermatology EMA said Aastrom's matrix-induced autologous chondrocyte implant (MACI) manufacturing site in Denmark has been closed. …

    Published on 10/6/2014
  • Cynvenio Biosystems sales and marketing update

    Cynvenio Biosystems Inc., Westlake Village, Calif. Business: Diagnostic Cynvenio launched an early access program to make its LiquidBiopsy genomic platform available to cancer research centers. The automated …

    Published on 10/6/2014
  • Eisai sales and marketing update

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Cancer Eisai launched Halaven eribulin in Australia to treat locally advanced or metastatic breast cancer. The synthetic analog of halichondrin B is available in at …

    Published on 10/6/2014
  • Novo Nordisk sales and marketing update

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Business: Endocrine/Metabolic Novo Nordisk launched Ryzodeg insulin degludec/insulin aspart in Mexico to treat Type II diabetes. Novo Nordisk said Mexico is the …

    Published on 10/6/2014
  • Shionogi sales and marketing update

    Shionogi & Co. Ltd. (Tokyo:4507), Osaka, Japan Business: Gastrointestinal Shionogi's C&O Pharmaceutical Technology (Holdings) Ltd. subsidiary launched rabeprazole sodium for injection in China to treat peptic ulcers. …

    Published on 10/6/2014
  • Anacor sales and marketing update

    Anacor Pharmaceuticals Inc. (NASDAQ:ANAC), Palo Alto, Calif. Business: Infectious Anacor said the Sandoz Inc. generics unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) launched Kerydin tavaborole in the U.S.…

    Published on 9/29/2014
  • Biotie, Lundbeck sales and marketing update

    Biotie Therapies Corp. (HSE:BTH1V), Turku, Finland H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Business: Neurology Biotie said Lundbeck launched Selincro nalmefene in France to reduce alcohol consumption in adults …

    Published on 9/29/2014
  • Clinigen Group sales and marketing update

    Clinigen Group plc (LSE:CLIN), Burton-on-Trent, U.K. Business: Infectious Clinigen launched Vibativ telavancin in Europe to treat hospital-acquired (nosocomial) pneumonia, including ventilator-associated pneumonia, …

    Published on 9/29/2014
  • Mobidiag sales and marketing update

    Mobidiag Ltd., Helsinki, Finland Business: Diagnostic Mobidiag launched Amplidiag Bacterial GE in Europe to screen for gastroenteritis-causing bacteria from stool samples. The PCR-based diagnostic has CE Mark approval.

    Published on 9/29/2014
  • Novartis, Omnicare sales and marketing update

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Omnicare Inc. (NYSE:OCR), Cincinnati, Ohio Business: Cancer Omnicare's Advanced Care Scripts (ACS) division was selected to be part of a limited starter-dose …

    Published on 9/29/2014
  • Roche sales and marketing update

    Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Diagnostic Roche launched its Elecsys Anti-Mullerian Hormone (AMH) blood test in "most" countries that recognize CE Mark approval to assess a woman's ovarian …

    Published on 9/29/2014
  • Vela Diagnostics sales and marketing update

    Vela Diagnostics, Singapore Business: Diagnostic Vela launched the Sentosa SQ Melanoma Panel to detect melanoma. The automated pipetting system for nucleic acid extraction and PCR setup simultaneously detects 127 hot …

    Published on 9/29/2014
  • Biocartis sales and marketing update

    Biocartis S.A., Lausanne, Switzerland Business: Diagnostic Biocartis launched its Idylla molecular diagnostics platform and Idylla BRAF Mutation Test in countries that accept CE Mark. Idylla is an automated, real-time …

    Published on 9/22/2014
  • Daiichi Sankyo, Mitsubishi Tanabe Pharma sales and marketing update

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Business: Endocrine/Metabolic Mitsubishi and Daiichi launched Canaglu canagliflozin in Japan to treat Type II …

    Published on 9/22/2014
  • Kyowa Hakko Kirin, Leo Pharma sales and marketing update

    Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Leo Pharma A/S, Ballerup, Denmark Business: Dermatology Kyowa launched Dovobet Ointment calcipotriene/betamethasone dipropionate in Japan to treat psoriasis vulgaris…

    Published on 9/22/2014
  • Panagene sales and marketing update

    Panagene Inc., Daejeon, South Korea Business: Diagnostic Panagene launched four products integrated with the company's C-melting technology, which detects mutations from circulating tumor DNA in blood. According to …

    Published on 9/22/2014
  • AstraZeneca sales and marketing update

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Endocrine/Metabolic, Drug delivery AstraZeneca launched Bydureon Pen for self-injection of once-weekly Bydureon exenatide in the U.S. to treat Type II …

    Published on 9/15/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993